The Validity of Retinal Blood Flow Measurements During Hyperoxia in Humans Using Fourier Domain Color Doppler Optical Coherence Tomography (CDOCT)
Noninvasive monitoring of blood flow in retinal circulation may elucidate the progression and treatment of ocular disorders, including diabetic retinopathy, age-related macular degeneration and glaucoma.
Laser Doppler velocimetry (LDV), a noninvasive optical method combined with vessel size determination has been used extensively as a valuable research tool to examine blood flow dynamics in the human retina. However, no information on the velocity profile within the vessel is available. Ophthalmic color Doppler optical coherence tomography (CDOCT) provides laser Doppler information in addition to conventional optical coherence tomography, allowing the observation of blood flow dynamics simultaneously to imaging retinal structure.
We have recently demonstrated the feasibility of Fourier domain CDOCT to assess velocity profiles in human retinal vessels in vivo.
In the present study the validity of Fourier domain CDOCT for retinal blood flow measurements will be tested at baseline and during hyperoxia-induced vasoconstriction in humans by comparison with retinal blood flow measurements using a commercially available LDV system and the Zeiss retinal vessel analyzer (RVA)
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||The Validity of Retinal Blood Flow Measurements During Hyperoxia in Humans Using Fourier Domain CDOCT|
- Retinal blood flow (LDV, RVA) [ Time Frame: 15 minutes ] [ Designated as safety issue: No ]
- Retinal venous diameters (Zeiss retinal vessel analyzer) [ Time Frame: 5 minutes ] [ Designated as safety issue: No ]
- Retinal blood velocity (laser Doppler velocimetry) [ Time Frame: 10 minutes ] [ Designated as safety issue: No ]
|Study Start Date:||September 2010|
|Study Completion Date:||January 2012|
|Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
12 healthy male subjects
Other: 100% Oxygen
100% Oxygen- breathing over 30 minutes
Please refer to this study by its ClinicalTrials.gov identifier: NCT00431600
|Department of Clinical Pharmacology|
|Vienna, Austria, 1090|
|Principal Investigator:||Gerhard Garhoefer, MD||Department of Clinical Pharmacology Medical University of Vienna|